154314-62-2

Basic information

• Product Name: 4-amino-2,6-difluorobenzoic acid
• CAS NO: 154314-62-2
• Molecular Weight: 173.119
• Mol File: 154314-62-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-amino-2,6-difluorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-2,6-difluorobenzoic acid(154314-62-2)
• EPA Substance Registry System: 4-amino-2,6-difluorobenzoic acid(154314-62-2)

Safety Data

• Hazardous Substances Data: 154314-62-2(Hazardous Substances Data)

Upstream product

• 154314-61-1 4-amino-2,6-difluorobenzamide 
• 1329166-92-8 4-(benzhydrylidene-amino)-2,6-difluoro-benzoic acid methyl ester 
• 191469-36-0 ethyl 2,6-difluoro-4-aminobenzoate 

Downstream Products

• 1028745-26-7 4-azido-2,6-difluorobenzyl phosphoramide mustard 
• 1028745-89-2 glutaryl-Hyp-Ala-Ser-Chg-Gln-NH-2,6-difluorobenzyl phosphoramide 
• 1028745-49-4 4-(Nα-trifluoroacetyl-L-glutaminyl)amido-2,6-difluorobenzyl phosphoramide 

Relevant articles and documents

Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen

A series of Glutaryl-Hyp-Ala-Ser-Chg-Gln-4-aminobenzyl phosphoramide mustard conjugates (1a-e) was designed and synthesized as potential prodrugs for site-specific activation by PSA in prostate cancer cells. All conjugates were found to be substrates of PSA with cleavage occurring between Gln and the para-aminobenzyl (PAB) linker. Structure-activity relationship studies on these conjugates indicated that introduction of electron-withdrawing fluorine(s) on the phenyl ring in the PAB linker uniformly improved the chemical stability of the conjugates while the position of substitution affected differently the self-immolative process of conjugates upon proteolysis. Introduction of a fluorine at ortho position to benzylic phosphoramide as in 1b results in better stability of the conjugate prior to activation while maintaining its antiproliferative activity upon activation by PSA. The conjugate 1b with 2-fluoro substitution was identified as a promising lead for further evaluation and optimization in the development of prostate cancer-targeted prodrugs.

MACROCYCLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Quinazoline derivatives as VEGF inhibitors

The invention relates to quinazoline derivatives of formula (I) STR1wherein: Z represents --O--, --NH-- or --S--; m is an integer from 1 to 5; R 1 represents hydrogen, hydroxy, halogeno, nitro, trifluorometlyl, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio or NR 5 R 6 (wherein R 5 and R 6, which may be the same or different, each represents hydrogen or C 1-3 alkyl); R 2 represents hydrogen, hydroxy, halogeno, methoxy, amino, or nitro; R 3 represents hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X 1 represents --O--, --CH 2 --, --S--, --SO--, SO 2 --, --NR 6 --, NR 8 CO--, --CONR 9 --SO 2 NR 10 -- or --NR 11 SO 2 --, (wherein R 7, R 8, R 9, R 10 and R 11 each represents C 1-3 alkyl, C 1-3 alkoxyC 2-3 alkyl); R 4 represents a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted 5 or 6 membered saturated carbocylic or heterocyclic group; and salts thereof, processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient the compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.